|
Orthologous residues
|
|
p70S6K (human): T252‑p, p70S6K iso2 (human): T229‑p, p70S6K (mouse): T252‑p, p70S6K (rat): T252‑p, p70S6K iso2 (rat): T229‑p, p70S6K (fruit fly): T238‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), CHO (fibroblast) [EphB1 (human), transfection]
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
hamster, human
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
serum
|
|
|
|
increase
|
|
|
insulin
|
|
|
|
increase
|
|
|
rapamycin
|
insulin
|
|
|
inhibit treatment-induced increase
|
|
|
wortmannin
|
insulin
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
enzymatic activity, induced
|